Brandon Capital

Institutional research briefing | 13 November 2026 | AUD unless otherwise stated

Brandon Capital Partners

Melbourne-headquartered specialist life sciences venture capital manager with investment operations spanning Australia, New Zealand, the UK and US.

1. Executive overview

Brandon Capital is one of Australia's most established specialist venture capital managers and provides a particularly useful case study in building a multi-fund institutional VC platform.

Its model combines conventional closed-end venture capital funds, government-supported investment vehicles, institutional limited partners, parallel fund structures and a proprietary research-commercialisation network.

Latest fund — BB6

A$439m

Final close, July 2025

Sum of seven disclosed fund sizes

A$1.22bn

Arithmetic total, including BB6; not current NAV or verified platform AUM

Investments historically

60+

Disclosed June 2024

Active portfolio

30+

Disclosed July 2025

Sources: July 2025 final close; June 2024 first close; historical fund disclosures and subsequent reporting of Fund V at A$250m.

Principal findings

• Fund structure: The latest A$439 million fund comprises four parallel trusts, with a bespoke debt arrangement accommodating the National Reconstruction Fund Corporation (NRFC). This is materially more sophisticated than a single-unit-trust VC structure.
• Investor base: HESTA, Hostplus, CSL, QIC, the Western Australian Government and the NRFC are among the disclosed investors in Fund VI.
• Government participation: Brandon has historically combined private institutional capital with government-supported programs, including the Biomedical Translation Fund.
• Portfolio strategy: Predominantly therapeutics, biotechnology and medical devices, with selective health technology exposure and a growing international portfolio.
• Investment model: Brandon often creates or seeds companies rather than simply investing in existing startups, then reserves capital for successive clinical development rounds.
• Fund duration: A historical disclosure describes 15-year fund lives, reflecting the extended development and commercialisation cycle of biomedical assets. Current fund terms need verification.
• Recent realisations: the completed Myricx acquisition is a major portfolio outcome. BB6 proceeds and investor distributions require confirmation by fund and co-investment vehicle.

The most important structural finding is that Brandon has developed a fund management platform that can accommodate different investor types and capital structures without abandoning a coherent investment strategy.

2. Fund history and capital raised

The fund numbering requires care. Brandon's fourth major vehicle was the Biomedical Translation Fund vehicle, known as MRCF BTF, rather than a fund called MRCF4.

Historical amounts are from Brandon’s disclosures; Fund V’s approximately A$250m final size is supported by BioCentury’s July 2025 report, while its A$210m first close was announced in 2019. The 2008 Brandon Biosciences fund is distinct from MRCF1.

Disclosed fund sizes / reported commitments

A$ million. Fund V uses its subsequently reported A$250m size.

The seven figures sum to A$1,220m: 11 + 50 + 40 + 200 + 230 + 250 + 439. This is the defensible total for the vehicles listed here. Brandon’s 2024 announcement refers to over A$1bn across five previous funds, wording repeated in substance in 2025; that claim does not reconcile with the individual sizes in this table. Do not add BB6 to it to assert A$1.4bn+ without a manager reconciliation, or assume the announcement necessarily includes BB6.

The amounts should not be confused with current funds under management, which change as capital is deployed, distributed and revalued.

Fund III: institutional capital and follow-on capacity

MRCF3 raised A$200m in 2015 from AustralianSuper, HESTA, Statewide Super and Hostplus. Around A$50m was allocated to 20–30 seed opportunities and A$150m to follow-on funding for promising new and existing companies through mid-stage clinical trials. Investors could also commit substantial additional capital directly to maturing assets. Contemporaneous launch coverage.

Public securities filings identify investor-specific MRCF3 trusts, including the MRCF3 (H) Trust and its corporate trustee. This supports a trust-based implementation; the full trust deeds and allocation agreements remain necessary to map all investors and vehicles. Filed investor agreement.

2016 government co-investment vehicle: MRCF-BTF

The A$230m vehicle paired A$115m of Commonwealth capital with A$115m from private investors. It should be distinguished from BB6’s later NRFC arrangement. Medicines Australia announcement.

The government’s published investee schedule identifies MRCF-BTF participation in Global Kinetics (jointly with another BTF manager), Aravax, GI Therapies, Certa Therapeutics, Respirion Pharmaceuticals, Denteric, George Medicines, PolyActiva, Axelia Oncology, ENA Respiratory, OccuRx and OncoRes. This is a historical program schedule, not a verified current holdings or NAV statement. Government investee list.

3. Fund structures — the most significant findings

Brandon's history is particularly informative because it demonstrates that its managers have used different legal and tax structures to address the limitations of Australian venture capital legislation.

3.1 Historical structures: VCLP plus parallel unit trust

A primary-source submission by Brandon to the Australian Board of Taxation provides unusually useful detail about its early fund structures.

Brandon explicitly explained that a parallel unit trust was useful when portfolio companies ceased to qualify for further investment by a VCLP, including after an ASX listing.

This matters because a fund investing in biomedical companies can face a situation where a successful investee becomes listed but still needs several years of development capital.

A parallel trust gives the manager additional investment flexibility, subject to the trust's own legal, tax and mandate restrictions.

Illustrative historical structure — BBF1

Conceptual representation of the documented A$50m BBF1 structure, not a complete legal entity chart.

3.2 Fund VI: four parallel trusts

Gilbert + Tobin, Brandon's legal adviser, confirmed that BB6 was structured through:

• Four parallel trusts.
• A novel debt arrangement to accommodate the NRFC.
• Institutional subscriptions from superannuation, corporate and government investors.
• Separate co-investment arrangements for selected investors.

These features are expressly described by Gilbert + Tobin. Its announcement does not disclose individual trustees, all tax classifications, fee waterfalls or investor allocations. Co-investment arrangements are confirmed for selected investors; they should not be assumed to apply to every investor.

3.3 The NRFC component

NRFC commitment

A$150m

34.2% of BB6 headline size

Other commitments: A$289m

The NRFC’s A$150m is dedicated to Australian medical science. Its own announcement says approximately one-third of its funding is for early-stage ventures, with the balance primarily supporting later-stage development. The public wording attaches that allocation to the NRFC investment; it does not establish an identical split for all BB6 capital.

The NRFC 2025–26 annual report, printed pages 22–23 reports A$60m invested in ten companies, including three seed or early-stage businesses, and A$273m of additional private capital. These are NRFC-reported outcomes; the A$273m is not extra BB6 fund commitments. Forbes Australia, 3 September 2026, separately reports A$60m across ten businesses and says three remain in stealth. Stealth status and development stage are different classifications.

This is evidence of a dedicated investment sleeve within the broader BB6 platform. It should not be assumed that the A$150 million commitment has identical economics or unrestricted access to the full international BB6 portfolio.

3.4 Regulatory arrangements

Brandon's current corporate website identifies two Australian financial services licensees:

These licences confirm that multiple regulated entities form part of the operating platform. They do not, by themselves, establish which entity is the trustee, responsible entity, investment manager or general partner of each individual fund.

It is also important not to assume that every Brandon fund is an ESVCLP or VCLP. The historical records establish VCLP and unit trust structures, while the latest BB6 disclosure establishes parallel trusts.

4. Portfolio composition and investment strategy

4.1 Portfolio maturity

Brandon reported the following position in July 2025:

Clinical trials

17

Advancing / in-market

4

These are manager-reported July 2025 counts, rather than a current or mutually exclusive portfolio breakdown. No percentage allocation is calculated from the “over 30” denominator.

This portfolio is substantially different from a conventional Australian technology VC portfolio. Much of the capital is tied to scientific, regulatory and clinical milestones rather than customer acquisition and recurring software revenue.

Brandon disclosed in 2019 that approximately 80% of its then portfolio companies focused on drugs and vaccines, with the balance in devices and platform technologies. This is a historical company-count mix, not a current capital allocation.

Portfolio counts: Brandon’s final close announcement, 24 July 2025, which expressly includes the four advancing or in-market companies.

BB6 geographic mandate

BioCentury’s June 2024 reporting described a target of roughly half of Fund VI in Australia and New Zealand, with the rest internationally. This is a fundraising-era target, not a verified deployed split after the NRFC commitment.

4.2 Representative portfolio companies

AdvanCell — Radiopharmaceuticals

Targeted alpha cancer therapies and a disclosed BB6 investment. On 15 July 2026, AdvanCell announced a US$315m Series D, with Brandon among the participating existing investors. Proceeds support clinical development and manufacturing expansion; this financing is not itself a Brandon exit. Company announcement.

PolyActiva — Ophthalmology

Sustained-release ocular implant technology, demonstrating Brandon's interest in specialist drug-delivery platforms.

Myricx Bio — Oncology

Historical holding and disclosed BB6 investment. Novartis agreed on 6 July 2026 to acquire Myricx for US$1.1bn upfront plus up to US$400m in milestones. Its Q3 release subsequently confirms completion. Myricx should therefore be shown as an acquisition outcome, rather than an ordinary current independent holding. Acquisition announcement; Q3 completion confirmation.

EBR Systems — Medical devices

Wireless cardiac stimulation technology, with US FDA approval announced in 2025.

Perx — historical digital health investment / restructuring

Perx’s own transaction notice says Clutch completed the US acquisition and the Australian business agreed to merge with Navigator Group; terms were undisclosed. Its webpage is dated 5 January 2026, while May deal coverage gives a later reporting date. The event should not be assigned a definitive May completion date from that coverage alone. Perx is a historical portfolio outcome, with any residual Brandon exposure unverified. Perx transaction notice.

Other disclosed holdings include CatalYm, Pheon Therapeutics, NRG Therapeutics, AstronauTx, Aravax, Certa Therapeutics, Vaxxas and Q-Sera.

These are manager-level portfolio examples across vintages, not a complete BB6 holdings schedule. Brandon's public information does not provide sufficient data to calculate a reliable company-by-company percentage of fund NAV or invested capital.

5. How Brandon sources and creates its investments

Brandon's competitive advantage is not simply the size of its funds. It is the institutional origination network built around Brandon BioCatalyst, formerly the Medical Research Commercialisation Fund collaboration.

The network includes more than 50 medical research institutes and research hospitals across Australia and New Zealand.

Brandon BioCatalyst’s investment page reports that more than 85% of the over 50 startups it supported were founded through its first investment. This is a manager-reported statistic for that network, not a proportion of all Brandon holdings or BB6. The same page describes member-institute representation on the Investment Review Committee.

Brandon's research-to-commercialisation model

50+ research institutes and hospitals

Scientific discovery and intellectual property

Brandon BioCatalyst

Origination, peer review, diligence and company formation

Brandon-managed funds

Seed capital, follow-on funding and co-investment

Commercialisation and exits

Clinical development, licensing, trade sale or IPO

This structure gives Brandon a potential advantage over a traditional VC manager reliant on external deal referrals. It can participate in company creation, IP commercialisation strategy, recruitment of management teams and subsequent financing.

It also creates an enduring source of investment opportunities across successive fund vintages.

CUREator: the grant-funded incubation layer

CUREator is the government-funded incubator delivered through Brandon BioCatalyst, supporting projects before or alongside conventional venture investment. Its guidelines distinguish milestone-based, non-dilutive grant funding from any subsequent equity financing and state that the program does not claim project IP. It strengthens the origination pipeline but should not be added to venture fund commitments. CUREator funding guidelines.

6. Economics, performance and exits

Public information is considerably less complete on fund economics than on capital raised.

The historical 20%+ net IRR figure is encouraging, but should not be extrapolated to MRCF5 or BB6. It is neither a current consolidated return nor a verified result for each fund.

Myricx: the most significant recent realisation

The US$1.1bn upfront Myricx acquisition, with up to US$400m in contingent milestones, materially changes the portfolio-outcomes discussion. Novartis’s announcement establishes transaction terms and its Q3 release confirms completion. Forbes described it as Brandon’s biggest single-investment return. Subsequent Forbes coverage.

Brandon identifies Myricx as a BB6 investment, while its involvement began before BB6. Proceeds could therefore span vintages or co-investors. Completion supports a realised outcome at company level, but public disclosures reviewed here do not establish BB6’s ownership, net proceeds, distribution timing or DPI uplift. Those figures must be obtained from Brandon; headline purchase consideration is not a fund return.

Notable commercial outcomes

Brandon's historical portfolio includes several examples of significant value creation:

• Spinifex Pharmaceuticals: Acquired by Novartis, with approximately US$200 million in upfront consideration announced.
• Fibrotech Therapeutics: Acquired by Shire for approximately US$75 million upfront, with potential additional consideration.
• EBR Systems: Advanced through an ASX listing and subsequent US regulatory approval of its cardiac technology.
• George Medicines: Progressed to US FDA approval of a hypertension treatment.

Spinifex and Fibrotech demonstrate historical trade-sale exits; EBR illustrates a longer path through public markets and regulatory milestones. Myricx adds a major completed acquisition. These company outcomes do not by themselves quantify distributions to a particular fund.

7. What the model tells us about institutional venture capital in Australia

Brandon illustrates five features of a mature Australian institutional VC manager.

First, fund size is linked to portfolio maturity. Brandon progressed from relatively small seed vehicles to funds capable of supporting companies through expensive clinical development and international expansion.

Second, parallel vehicles are commercially useful. Its historical VCLP/unit-trust arrangements addressed investment eligibility restrictions, while BB6's four-trust architecture accommodates a more diverse institutional investor base.

Third, government capital can anchor institutional fundraising. The NRFC's A$150 million participation represents approximately 34% of BB6's headline size, although the legal and economic treatment of that commitment differs from an ordinary unrestricted LP subscription and requires closer examination.

Fourth, co-investment capacity can materially increase deployable capital. Brandon explicitly maintains co-investment arrangements with its investors. This enables it to support large financing rounds without necessarily concentrating all exposure within the flagship fund.

Fifth, the origination network is a strategic asset. The research-institute collaboration supports proprietary company formation and creates a differentiated source of investments.

For a manager seeking to build an institutional venture platform, the key lesson is the combination of repeatable origination, patient institutional capital, flexible fund structuring and demonstrated realisations.

8. Outstanding diligence questions

For a more complete institutional assessment, I would seek the following information directly from Brandon:

9. Sources and evidence register

Primary documents are preferred. Trade reporting is identified where used; dates and portfolio statistics retain their original reporting periods.

1. Gilbert + Tobin — BB6 structure, NRFC debt arrangement and selected-investor co-investment
2. Brandon Capital — June 2024 Fund VI first close, historical investment count and aggregate-capital wording
3. Brandon Capital — July 2025 final close, investors, portfolio counts and AFSL disclosures
4. NRFC — A$150m commitment and allocation statement
5. NRFC Annual Report 2025–26 — printed pages 22–23: deployment, stages and private capital
6. Brandon BioCatalyst — company creation and investment-review process
7. Novartis — 6 July 2026 Myricx acquisition agreement
8. Novartis Q3 2026 release — Myricx completion
9. AdvanCell — 15 July 2026 US$315m Series D
10. Perx — dual strategic transactions and undisclosed terms
11. Medicines Australia — 2016 A$115m / A$115m matching structure
12. Australian Government — BTF investee companies
13. Public securities filing — MRCF3 (H) trust and trustee
14. CUREator — grant guidelines and separation from equity funding
15. BiotechDispatch — contemporaneous MRCF3 launch coverage (trade reporting)
16. BioCentury — July 2025 BB6 close and Fund V reported A$250m size (trade reporting)
17. BioCentury — June 2024 geographic target (trade reporting)
18. Forbes Australia — September 2026 NRFC deployment and stealth status (press reporting)
19. Brandon submission to the Board of Taxation — historical VCLP and parallel unit trusts
20. Brandon’s reproduction of 2019 coverage — Fund V first close, historical sector mix, term and return disclosures

Overall assessment

Brandon Capital is a strong case study of how an Australian specialist venture manager can scale from relatively modest funds into a platform attracting superannuation, corporate and government capital.

The most distinctive finding is its evolution from a VCLP with a parallel unit trust into a multi-trust institutional platform incorporating bespoke government financing and co-investment rights.

The principal research gap is fund-level financial transparency. Public disclosures establish the platform's scale, investment strategy and selected outcomes, but do not establish its current net performance, portfolio valuations, detailed fee economics or complete fund ownership structure.

For an institutional comparison or fund-platform design exercise, those are the next areas I would investigate.

10. Acquisition potential: management business, fund interests or both

Transaction analysis as at 13 November 2026. The structures and terms below are proposals for discussion, not disclosed Brandon terms, a valuation or evidence of a sale process. No reviewed evidence establishes seller willingness, the ownership of the management entities or the required contractual consent thresholds.

10.1 Define exactly what would be purchased

“Buying the fund” should therefore be defined as buying investor interests, buying assets, or changing the manager. Buying every investor’s interest would require all relevant interests to be transferable and all necessary sellers and approvers to agree; no compulsory acquisition right has been established. A trustee’s legal title to assets is a fiduciary role, not beneficial ownership available to the trustee’s shareholder.

10.2 Brandon-specific feasibility and constraints

• People and origination are central to value. The research network, company formation capability and scientific judgement are difficult to replace. Confirm employment, investment-committee membership, institute agreements, IP and brand rights. Buying the operating company does not establish ownership of the BioCatalyst collaboration or its institutional relationships.
• BB6 is a multi-vehicle acquisition problem. Four parallel trusts and a bespoke NRFC debt arrangement mean the buyer must map mandates, trustees, fees, carry and rights across each sleeve. The NRFC’s A$150m cannot be treated as an ordinary transferable LP stake or assumed to remain after a control change. Review lender consent, repayment, security and change-of-control provisions. Gilbert + Tobin’s structure disclosure.
• BTF can constrain the combined model. Section 8.2 of the program guidelines generally prevents a licensed-fund investor from influencing individual investment decisions or being a shareholder in, or otherwise controlling, the manager unless the Programme Delegate approves; an exception is stated for key personnel. A minority manager stake is therefore not necessarily a solution. Obtain a ruling on the actual buyer group and associates; separate SPVs do not establish compliance. Section 8.3 leaves fund-interest disposals, structural changes, licence transfers and manager retirement to governing documents. BTF guidelines, sections 8.2–8.3.
• Older fee streams may be running off. The BTF guidelines state that management fees beyond ten years require Programme Delegate and Advisory Board agreement. For a 2016 vehicle, licence date and any extension are immediate diligence priorities. A historical 15-year fund life does not establish 15 years of unchanged fees. BTF guidelines, section 8.1.
• Myricx changes the acquisition perimeter. Reconcile sale proceeds, distributions, contingent milestones and carry at the pricing date. Do not buy a NAV containing cash already distributed, assume historical Myricx proceeds belong to BB6, or pay twice for carry held outside the management company.

10.3 Proposed working structure: staged platform acquisition with selective liquidity

The diagram is conceptual. Separate vehicles improve accounting and funding clarity; they do not remove common-control, associate, conflicts or regulatory issues.

Corporate reserved matters might cover leverage, new share issuance, related-party dealings and material strategy changes. Individual portfolio decisions should remain with a competent investment committee under each fund’s mandate, with recusals for conflicts. Legacy carry, future carry and manager equity should each be negotiated explicitly; none should be assumed to transfer together.

A secondary offer should be optional and independently assessed. Do not condition better portfolio pricing on an investor supporting the manager acquisition. If both components are essential to the buyer’s economics, use transparent, limited cross-conditions in the acquisition agreements, rather than hidden subsidies between investors and selling partners.

10.4 Valuation and funding model

Value the manager from contractual earnings, not headline capital raised. Build a fund-by-fund cash-flow forecast of fee bases, rates, step-downs, expiry, offsets and termination rights. Deduct market-rate compensation, retention costs, compliance and operating expenses. Value future fundraising as a separate probability-weighted scenario, not guaranteed revenue. Add only the carried-interest rights actually included, using expected net distributions after vesting, hurdles and clawback exposure. Then adjust for corporate cash, debt and working capital. Current disclosures do not support a credible Brandon purchase-price estimate.

Value fund interests from remaining net cash flows. Start with a reconciled reference-date NAV, test each investment’s clinical, financing and exit scenarios, and deduct expected future calls, fees, carry and liabilities. Unfunded commitments are an obligation, not an asset purchased for cash. A discount to NAV is a pricing convention, not proof of value; an optimistic clinical valuation can remain expensive at a discount.

This example demonstrates cash requirements only; it does not establish expected returns. Total sponsor funding would additionally include the separately negotiated manager consideration, manager working capital and any primary capital. For an asset-sale continuation, add the vehicle’s own follow-on budget; avoid counting reserves already included in assumed commitments twice.

For manager consideration, consider an upfront payment for retained contractual fee earnings, a deferred payment tied to actual mandate retention and separately priced participation in specified legacy carry. Allocate escrow or contractual protection for clawbacks and pre-acquisition liabilities. Model retained team economics before determining what is available to the buyer. Acquisition debt should be serviced from buyer/manager cash flows without assuming access to investor assets or capital calls.

10.5 Consent, regulation and conflicts

10.6 Negotiating agenda and decision gates

1. Establish seller appetite and purpose: founder liquidity, succession, growth capital or an investor liquidity request. Ask whether a minority partnership, control sale or selected mandate transfer is even available.
2. Obtain the acquisition data room: ownership chart, audited manager accounts, fee schedules, all fund deeds and side letters, carry/vesting/clawback arrangements, GP commitments, employment terms, NRFC facility and BTF/grant documents.
3. Test the portfolio independently: latest holdings, ownership and preference terms, clinical milestones, cash runway, future funding needs and exit scenarios. Reconcile Myricx cash and milestones and identify residual Perx exposure.
4. Confirm anchor-investor and government pathways: identify the necessary approvers before making a binding commitment; retain commercial confidentiality and avoid assuming one investor speaks for all parallel vehicles.
5. Agree separate term sheets and models: manager stake, any legacy carry purchase, secondary interests and future primary funding each receive their own price, economics, conditions and sources of finance.
6. Proceed only if the platform remains viable: sufficient mandates survive, key scientists and investors remain engaged, near-term follow-ons are funded and government conditions are workable. If manager consent fails but attractive transfers remain possible, pursue portfolio exposure alone. If combined BTF ownership is prohibited or approval is refused, exclude it or abandon that component.

Recommended negotiating position: explore a retained-team, staged platform partnership with optional investor liquidity, rather than opening with a proposal to acquire every fund. The central commercial test is whether durable fee earnings, retained talent and independently underwritten portfolio exposure justify their separate prices. A full buyout becomes a later option once ownership, consent and funding risks are resolved.